Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Real-world data backs Pepaxti for tough-to-treat myeloma. Two independent European studies — one from Spain (40 patients) and one from Italy (42 patients) — found that Pepaxti (melflufen) plus dexamethasone delivered meaningful responses and manageable side effects in heavily pretreated relapsed/refractory multiple myeloma, including patients who had already received anti-BCMA or anti-GPRC5D immunotherapies. The findings will be presented at ASH 2026 in December.
Real-world data backs Pepaxti for tough-to-treat myeloma
Two independent European retrospective studies are adding to the evidence base for Pepaxti (melflufen) in relapsed/refractory multiple myeloma (RRMM). Conducted across 26 Spanish centers and 8 Italian centers, the studies enrolled a combined 82 heavily pretreated patients — most with 4 prior lines of therapy — and will be presented at the 68th ASH Annual Meeting in New Orleans this December.
Both studies showed clinically meaningful activity and a predictable, manageable safety profile, even in patients who had previously received cutting-edge immunotherapies like anti-BCMA and anti-GPRC5D agents. The Italian cohort also highlighted Pepaxti's role as a "bridge" therapy, with 67% of patients able to move on to subsequent novel treatments, including CAR-T cell therapy and bispecific antibodies.
By the Numbers
Why it matters: As immunotherapies move earlier in myeloma treatment, physicians urgently need effective options for patients who relapse afterward. These real-world findings suggest Pepaxti can fill that gap — offering disease control and even serving as a bridge to the next line of therapy.
